🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Glad to have our team answer more questions about our novel, national decentralized PhII, IND trial. We're so excited about the approach. NIH Pragmatic Trials Collaboratory Duke Clinical Research Institute Yale School of Medicine Yale Center for Infection and Immunity YaleClinicalResearch #digitalhealth #clinicaltrials #LongCovid Prof. Akiko Iwasaki rethinkingclinicaltrials.org/news/december-…

Dr. Harlan Krumholz has been named editor-in-chief of the Journal of the American College of Cardiology (JACC Journals). Harlan Krumholz has been at Yale for over 3 decades & is one of the world's most cited researchers. Learn more about Krumholz & his new role. medicine.yale.edu/intmed/news-ar…

Congratulations to Harlan Krumholz, professor of medicine at @yalemed and director of the @ynhh Center for Outcomes Research and Evaluation, on being named next editor-in-chief of American College of Cardiology: jacc.org/announcements/… JACC Journals Yale Internal Medicine

Good-Bye Overnight Call, A #ProgramDirectorsNote to my Yale IM Traditional Residency Program residents. Yale Internal Medicine Twenty-eight hour call is ending in our residency, beginning next June. medicine.yale.edu/intmed/news-ar…

Our #LongCovid paper on 'Characterisation of internal tremors and vibration symptoms' is now published BMJ_Open; giving voice to what people are experiencing. Great team effort. Yale School of Medicine Yale Center for Infection and Immunity bmjopen.bmj.com/content/13/12/…

In this prospective observational study, we examined changes in symptoms & immune phenotypes in vaccine-naïve people with #LongCovid after COVID-19 vaccination. Due to the timing of the initiation of this study, we were only able to recruit 16 people. However, the insights we

Participant-centric, decentralized registries & trials- next-gen patient-centered research. Inclusive, partnered, decentralized, convenient – one IRB, no contract, direct-to-consumer. Ph II, IND, trial - here are the Methods. Results soon. Yale School of Medicine American Journal of Medicine sciencedirect.com/science/articl…

Honored to take on the role of the Lancet Asia-Pacific Commissioner! Excited to work with experts across the region.💪

The DOM-CovX Explorer & Repository, with its large-scale, standardized COVID-19 data has fostered collaboration, promoted diversity of scholarly pursuits and expanded medical education at Yale School of Medicine. Applications beyond COVID-19 are promising🙌 F. Perry Wilson, MD MSCE formative.jmir.org/2024/1/e52120/

Last week at #KidneyWk sharing findings on the barriers perceived by healthcare providers and patient-level factors associated with prescription of SGLT2i in patients with CKD. Thanks to our amazing mentor Sherry Mansour !!✨American Society of Nephrology Yale Nephrology Yale School of Medicine

🚨Special moment for me!🗝️ results of the American Heart Association 💸project RE valid tools for using #ICD10 codes for identifying #PE in #EHR data presented at The VIVA Foundation w sim pub JTH 👇 tinyurl.com/mrx3czsp Methods were prespecified Thrombosis & Haemostasis, TH,TH Open: tinyurl.com/mrxry3rz

César Caraballo Cordovez presenting at #acvc2025 in Florence!! Yale Cardiology Yale School of Medicine Yale Medicine

We’re excited to introduce our Yale Internal Medicine Chief Residents for 2026-27! Congratulations to all! Yale IM Traditional Residency Program medicine.yale.edu/internal-medic…

Hail to the Chiefs 🎊🎉 Congratulations to Aram Bidikian, César Caraballo Cordovez, Charlie Marvil, Sierra Mendelson, Kylie Rostad, Christina Cotte, Rose Gedeon, and Emily-Rose Zhou. The future of our program is bright ❤️❤️ Mark D. Siegel Yale Internal Medicine Yale School of Medicine

César Caraballo Cordovez young investigator finalist! Yale Medicine

Welcome JCF-I Associate Editor Dr. Elliott Miller. Dr. Elliott Miller is an Assist. Prof. at Yale School of Medicine & Medical Dir. of the Cardiac ICU at Yale New Haven Hospital. His research focuses on the intersection of critical care & cardiovascular medicine.

1/5 🔥 Hot off the press — PAXLC trial results now in The Lancet Infectious Diseases （🇯🇵日本語解説付き） After 3 years of dedicated work, we’re proud to share results from PAX LC: a fully decentralized, double-blind, placebo-controlled, FDA-authorized Phase 2 trial of Paxlovid

3/5 📉Primary outcome: Did Paxlovid improve physical health by Day 28? No. There was no significant difference between groups: • Paxlovid: +0.45 vs Placebo: +1.01 • Adjusted difference: –0.55 (95% CI: –2.32 to 1.21; p = 0.54) This falls well short of the 5-point threshold for

Antiviral medications nirmatrelvir/ritonavir (Paxlovid) were not effective in relieving Long COVID symptoms, according to a new study published in The Lancet Infectious Diseases on April 3. Read more here: brnw.ch/21wRUix #paxlovid #longcovid #covid #antiviral